Q2 sales came under pressure due to de-stocking and lockdown-related disruptions across the segments, though the momentum was partly offset by a strong show in Dupixent. Combined with effective cost management, the operating margin expanded during the quarter. While a recovery to pre-COVID levels would take time, the rising risk of the second wave of Coronavirus and seasonal flu should ensure high demand for the high-margin Influenza vaccines in H2. Top this up with the COVID-19-related oppor ....